A New Breast Cancer Drug Improves Survival Rate By 30 Percent

Scanning electron micrograph of a single prostate cancer cell

Scanning electron micrograph of a single prostate cancer cell

It is typically treated by therapies that block the hormone's production. "This corresponded to a 29 per cent lower risk of death in patients receiving the combination therapy".

Meanwhile, the results of a current study were presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Saturday and would be published today, June 4, 2019, in the New England Journal of Medicine. "This is an important group to study since advanced breast cancer is the leading cause of cancer death in women 20 to 59, and the vast majority of breast cancer is hormone-receptor positive".

"This is the first study to show improved survival for any targeted therapy when used with endocrine therapy as a first-line treatment for advanced breast cancer", Hurvitz said. "That's what is so phenomenal about the data".

The new trial, which looked at more than 670 cases, included only women who had advanced cancer - stage four for which they had not received prior hormone-blocking therapy. "The use of ribociclib as a frontline therapy significantly prolonged overall survival, which is good news for women with this bad disease". Burstein was not involved in the research.

Breast cancer causes the greatest number of cancer-related deaths among women globally.

"This class of drugs, and the way it slows cancer growth, represents one of the greatest advances in breast cancer research in recent decades, and it's vital we ensure that all patients who could benefit are able to access it".

Approximately 268,000 new cases of breast cancer are expected to be diagnosed in women in the U.S. this year, while the advanced form of the disease is the main cause of cancer deaths among women aged 20 to 59.

Researchers observed female breast cancer patients in a clinical trial with a 42-month follow-up window.

Even though advanced breast cancer is not very common among women of younger age, its occurrence grew by 2% per year over the period between 1978 and 2008 in the United States for the women aged between 20 and 39.

The study may also stimulate further research into whether the combination of ribociclib and other types of drug that are now not approved by the National Institute for Health and Care Excellence could help another class of breast cancer patients - those who have received prior hormone therapy.

The most common adverse reaction to the drug was a lowered white blood cell count, which can lead to infections.

The study was funded by pharmaceutical manufacturer Novartis which manufactures ribociclib under the name Kisqali. The drug, which is taken in pill form, costs over $12,000 a month, according to the prescription pricing website GoodRx.